|
TANAKA Junji
Department Other, Other Position |
|
| Article types | Original article |
| Language | English |
| Peer review | Peer reviewed |
| Title | Occurrence of adverse events caused by valganciclovir as pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration. |
| Journal | Formal name：Transplant infectious disease : an official journal of the Transplantation Society Abbreviation：Transpl Infect Dis ISSN code：(1399-3062)1398-2273(Linking) |
| Domestic / Foregin | Foregin |
| Volume, Issue, Page | 17(6),pp.810-815 |
| Author and coauthor | Takahata M†, Hashino S, Nishio M, Sugita J, Shigematsu A, Onozawa M, Fujimoto K, Endo T, Kondo T, Tanaka J, Imamura M, Teshima T |
| Publication date | 2015/12 |
| Summary | Low-dose VGCV was not inferior in clinical efficacy, including clearance rate of CMV antigenemia and incidence of consequent CMV disease, to standard-dose VGCV as was previously reported. Initial low-dose VGCV for pre-emptive CMV therapy markedly reduces hematologic toxicity and has clinical efficacy equivalent to that of standard-dose VGCV. It is therefore reasonable for patients, except for noticeably overweight patients, to be given initial low-dose VGCV. |
| DOI | 10.1111/tid.12456 |
| PMID | 26354293 |